Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613405 | 0.95 | ADRB1 (0.55) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL18646457 | 0.91 | TLR2 (0.51) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL18613406 | 0.91 | NPY1R (0.53) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL29627098 | 0.88 | ADRB2 (0.52) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL2473791 | 0.87 | ADRB1 (0.65) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL26263682 | 0.85 | TLR2 (0.53) | ADRB2ADRB1TLR2 | |
| SCHEMBL30515407 | 0.84 | NPY1R (0.58) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL8892157 | 0.82 | ADRB1 (0.66) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL13077582 | 0.81 | ADRB1 (0.54) | ADRB2ADRB1NR3C1CYP2D6ADRA1A | |
| SCHEMBL13040110 | 0.79 | ADRB1 (0.53) | ADRB2ADRB1NR3C1CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738087-B2 | Lymph directing prodrugs | MONASH UNIVERSITY (AU) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738087-B2 | Lymph directing prodrugs | MLNR, ABCB11, MLN | ADRB2 3316/4885ADRB1 3319/4885NR3C1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.